Dr. Reddy’s anti-migraine drug gets US FDA nod

Dr. Reddy’s Laboratories Ltd. has received approval from the US Food and Drug Administration (US FDA) for ZembraceSymTouch (Sumatriptan Succinate) injection, a drug-device combination product intended for the treatment of acute migraine in adults. It is available as a prefilled, ready-to-use, single dose disposable auto injector containing 3 mg of Sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously. “ZembraceSymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option,” Mr. Raghav Chari, Executive Vice-President, Proprietary Products Group, Dr.Reddy’s,said in a release.

Add a Comment